Pramodini Medicare IPO
Healthcare • ₹69.04 Cr
High risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- Heavy dependence on government or PSU customers
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹118
Lot Size
1200 shares
Issue Size
₹69.04 Cr
Open
12 Aug 2026
Close
14 Aug 2026
Subscription
3.63×
IPO Schedule
| Issue Open Date | 12 Aug 2026 |
| Issue Close Date | 14 Aug 2026 |
| Allotment Date | 17 Aug 2026 |
| Listing Date | 18 Aug 2026 |
About Pramodini Medicare
Pramodini Medicare is a diagnostic service provider in India, offering technology-enabled diagnostic services to public and private hospitals, government PSUs and medical colleges across tier I, tier II and tier III cities. Its services are divided into three categories: radiology, clinical laboratory and nuclear medicine. Radiology services include MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, Dexa scans and interventional radiology. Clinical laboratory services cover haematology, microbiology, immunology, pathology and biochemistry, while nuclear medicine services include PET-CT, SPECT and nuclear therapy. The company also provides teleradiology services through its registered office in Vijayawada, which operates 24×7. As of December 31, 2025, the company operated 15 diagnostic centres across six states and 13 cities in India. Its centres operate through public-private partnerships, private-private partnerships, strategic partnerships with government PSUs and standalone private centres. The company also has a processing unit-cum-laboratory in Vijayawada. Use of proceeds: The IPO consists of both a fresh issue of shares and an offer for sale (OFS). Proceeds from the OFS will go to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Funding of capital expenditure for purchase of medical equipment towards existing and proposed diagnostic centres — Rs 45.15 crore General corporate purposes.
Company Details
Founders / Promoters
Dr. Chalasani Kuldeep Kumar
Founded
2000
Registrar
PURVA
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Pramodini Medicare — IPOFins Verdict
QuantitativeDriven by QIB demand at 3.7x and elevated disclosed risk (7/10), Pramodini Medicare listed at a premium of 1.7% to its issue price. SME listings are also thinner and more volatile after listing. The picture is mixed — treat this as one input alongside the DRHP, valuation, and your own risk appetite.
- The company has a presence across six states and 13 cities in India. As of December 31, 2025, it operated 15 diagnostic centres across Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NC
- The company operates through four different service models. As of December 31, 2025, it had seven centres under public-private partnerships, three under private-private partnerships, three through str
- The company claims to have a diversified diagnostic equipment base. As of December 31, 2025, its operations were supported by seven CT machines, seven MRI machines, 20 X-ray machines, two Dexa scan ma
- The company provides services to B2G, B2B and B2C customers. For the nine months ended December 31, 2025, government-related business contributed 61.32% of revenue from operations, while B2B and B2C c
- The company claims to have technology-enabled diagnostic capabilities across radiology and pathology. Its radiology services use MRI, CT, X-ray, ultrasound, Dexa scan and mammography equipment, while
Score breakdown — what drove this verdict
High risk from DRHP → score -0.8
Institutional subscription → score +1.0
Actual listing outcome → score +0.5
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹118
Listing Price
₹120
Listing Gain/Loss
+1.69%
Listing Date
18 Aug 2026
Price Since Listing
Returns are measured against the ₹118 issue price.
Listing
₹120
+1.7%
Current
₹120
+1.7%
Want to buy this stock?
Trade Pramodini Medicare on the secondary market
FAQ
What is the price band of Pramodini Medicare IPO?
The price band is ₹118 per share with a lot size of 1200 shares. Minimum investment: ₹1,41,600.
What does Pramodini Medicare do?
Pramodini Medicare is a diagnostic service provider in India, offering technology-enabled diagnostic services to public and private hospitals, government PSUs and medical colleges across tier I, tier II and tier III cities. Its services are divided into three categories: radiology, clinical laboratory and nuclear medicine. Radiology services include MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, Dexa scans and interventional radiology. Clinical laboratory services cover haematology, microbiology, immunology, pathology and biochemistry, while nuclear medicine services include PET-CT, SPECT and nuclear therapy. The company also provides teleradiology services through its registered office in Vijayawada, which operates 24×7. As of December 31, 2025, the company operated 15 diagnostic centres across six states and 13 cities in India. Its centres operate through public-private partnerships, private-private partnerships, strategic partnerships with government PSUs and standalone private centres. The company also has a processing unit-cum-laboratory in Vijayawada. Use of proceeds: The IPO consists of both a fresh issue of shares and an offer for sale (OFS). Proceeds from the OFS will go to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Funding of capital expenditure for purchase of medical equipment towards existing and proposed diagnostic centres — Rs 45.15 crore General corporate purposes.
Should I apply for Pramodini Medicare IPO?
Pramodini Medicare listed at ₹120 (+1.7% premium to the ₹118 issue price) after 3.6x subscription. IPOFins Score 5/10: Driven by QIB demand at 3.7x and elevated disclosed risk (7/10), Pramodini Medicare listed at a premium of 1.7% to its issue price. SME listings are also thinner and more volatile after listing. The picture is mixed — treat this as one input alongside the DRHP, valuation, and your own risk appetite.
Who founded Pramodini Medicare?
Pramodini Medicare was founded by Dr. Chalasani Kuldeep Kumar in 2000.